An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Biologic License Application (BLA): 761137
Company: ASTELLAS

Patient Information Sheet

Products on BLA 761137

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
PADCEV	ENFORTUMAB VEDOTIN-EJFV	20MG/VIAL	INJECTABLE;INJECTION	Prescription	None	No	No
PADCEV	ENFORTUMAB VEDOTIN-EJFV	30MG/VIAL	INJECTABLE;INJECTION	Prescription	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for BLA 761137

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
12/18/2019	ORIG-1	Approval		N/A	Label (PDF) Letter (PDF) Review	Accelerated Approval	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761137Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761137Orig1s000TOC.html

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
11/21/2025	SUPPL-32	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761137s032lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/761137Orig1s032ltr.pdf
02/27/2025	SUPPL-29	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761137s029lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/761137Orig1s029ltr.pdf
12/15/2023	SUPPL-25	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761137s024s025lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761137Orig1s024; s025ltr.pdf
12/15/2023	SUPPL-24	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761137s024s025lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761137Orig1s024; s025ltr.pdf
04/03/2023	SUPPL-20	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761137s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761137Orig1s020ltr.pdf
04/18/2023	SUPPL-19	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761137s019lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761137Orig1s019ltr.pdf
04/03/2023	SUPPL-18	Supplement	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761137Orig1s018ltr.pdf
10/28/2022	SUPPL-17	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761137s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761137Orig1s017ltr.pdf
07/09/2021	SUPPL-8	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s006s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761137Orig1s006, s008ltr.pdf
03/22/2021	SUPPL-7	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761137Orig1s007ltr.pdf
07/09/2021	SUPPL-6	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s006s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761137Orig1s006, s008ltr.pdf

Labels for BLA 761137

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
11/21/2025	SUPPL-32	Efficacy-New Indication	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761137s032lbl.pdf
02/27/2025	SUPPL-29	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761137s029lbl.pdf
12/15/2023	SUPPL-25	Efficacy-Accelerated Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761137s024s025lbl.pdf
12/15/2023	SUPPL-24	Efficacy-New Patient Population	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761137s024s025lbl.pdf
04/18/2023	SUPPL-19	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761137s019lbl.pdf
04/18/2023	SUPPL-19	Labeling-Patient Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761137s019lbl.pdf
04/03/2023	SUPPL-20	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761137s020lbl.pdf
04/03/2023	SUPPL-20	Labeling-Patient Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761137s020lbl.pdf
10/28/2022	SUPPL-17	Labeling-Patient Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761137s017lbl.pdf
10/28/2022	SUPPL-17	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761137s017lbl.pdf
07/09/2021	SUPPL-8	Efficacy-Accelerated Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s006s008lbl.pdf
07/09/2021	SUPPL-6	Efficacy-New Patient Population	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s006s008lbl.pdf
03/22/2021	SUPPL-7	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s007lbl.pdf
12/18/2019	ORIG-1	Approval	Label (PDF)	Accelerated Approval	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf

Top